TEX46 and neoplasm: In our study, AMD delivered to tumor-bearing hosts simultaneously inhibited TEX release, altered TEX molecular content to a less immunosuppressive phenotype, and restored anti-tumor immune functions, providing a compelling rationale for repurposing AMD as a cancer drug.